Article Details
Retrieved on: 2021-08-09 14:59:11
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing ...
Article found on: www.investorsobserver.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here